Correlated Drug Terms (1)

---

	Name (Synonyms)	Correlation
drug1634	Non-convalescent fresh frozen plasma (Standard plasma) Wiki	1.00

Correlated MeSH Terms (9)

---

	Name (Synonyms)	Correlation
D025241	Spondylarthritis NIH	1.00
D001167	Arteritis NIH	0.71
D012859	Sjogren's Syndrome NIH	0.71
D001327	Autoimmune Diseases NIH	0.58
D011111	Polymyalgia Rheumatica NIH	0.58
D013700	Giant Cell Arteritis NIH	0.58
D008180	Lupus Erythematosus, Systemic NIH	0.41
D001172	Arthritis, Rheumatoid NIH	0.38
D001168	Arthritis NIH	0.29

Correlated HPO Terms (5)

---

	Name (Synonyms)	Correlation
HP:0012089	Arteritis HPO	0.71
HP:0002960	Autoimmunity HPO	0.58
HP:0002725	Systemic lupus erythematosus HPO	0.41
HP:0001370	Rheumatoid arthritis HPO	0.38
HP:0001369	Arthritis HPO	0.29

Primary Outcomes

Description: The number and proportion of patients with the normal body temperature (≤37.2 C) at the days 1, 2, 3, 4, 5, 6, 7 after the start of therapy, for the statistical data comparison between the two arms.

Measure: The number and proportion of patients with the normal body temperature (≤37.2 C) at the day 1, 2, 3, 4, 5, 6, 7 after the start of therapy

Time: Days 1, 2, 3, 4, 5, 6, 7

---

Secondary Outcomes

Description: For each patient, the number of days passed from the plasma administration to placing on mechanical ventilation will be noted, for the statistical data comparison between the two arms.

Measure: Days before mechanical ventilation

Time: 30 days

---

Description: For each patient, the number of days he or she spent on the oxygen support after the plasma administration will be noted, for the statistical data comparison between the two arms.

Measure: Days of need for oxygen therapy

Time: 30 days

---

Description: For each patient, the entire duration of ICU stay after the plasma administration will be noted, for the statistical data comparison between the two arms.

Measure: Days of stay in the ICU

Time: 30 days

---

Description: For each patient, the entire duration of hospital stay after the plasma administration will be noted, for the statistical data comparison between the two arms.

Measure: Days of hospitalization

Time: 30 days

---

Description: Changes of the plasma levels of the SARS-CoV-2 antibodies, days 14 and 30 after the treatment start vs those levels before the treatment start (day 0) for the same patients.

Measure: Changes of the titer of the SARS-CoV-2 antibodies in the blood plasma of patients

Time: Days 0, 14, 30

---

Description: Changes of the plasma levels of IL2, IL6, IL10, TNFalpha and INFgamma, days 3 and 7 after the treatment start vs those levels before the treatment start (day 0) for the same patients.

Measure: Dynamics of the cytokine profile

Time: Days 0, 3, 7

---

Description: Incidence of administering IL6 receptor blockers (tocilizumab, sarilumab)

Measure: Incidence of the cytokine storm development and the need of administering cytokine storm inhibitors

Time: Days 3, 7

---

Description: Changes of the plasma levels of C-reactive protein, days 1, 2, 3, 4, 5, 6, 7 after the treatment start vs those levels before the treatment start (Day 0) for the same patients.

Measure: Dynamics of the level of C-reactive protein

Time: Days 0, 1, 2, 3, 4, 5, 6, 7

---

Description: 30-day mortality rate, for the statistical data comparison between the two arms.

Measure: 30-day mortality rate

Time: 30 days

---